Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Summary

This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).

Timeline

Start

2022-09-30

Primary completion

2025-05-10

Completion

2025-06-10

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 tablet” ascletis.com ↗

Drugs

Indications